8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Apr 30, 2026·SEC
Lexicon Pharmaceuticals, Inc.(LXRX)Earnings, Financials & Key Ratios
LXRX•NASDAQ
Price updated Jun 19, 2026
AboutLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.Show more
- Revenue$50M+60.2%
- EBITDA-$48M+75.4%
- Net Income-$50M+74.9%
- EPS (Diluted)-0.14+77.8%
- Gross Margin99.45%+1.5%
- EBITDA Margin-96.96%+84.7%
- Operating Margin-98.21%+84.5%
- Net Margin-101.08%+84.3%
- ROE-39.72%+76.3%
LXRX Key Insights
Lexicon Pharmaceuticals, Inc. (LXRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 15.7%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 13.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LXRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LXRX Price & Volume
Lexicon Pharmaceuticals, Inc. (LXRX) stock price & volume — 10-year historical chart
Loading chart...
LXRX Growth Metrics
Lexicon Pharmaceuticals, Inc. (LXRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-9.15%
5 Years15.72%
3 Years610.25%
TTM123.12%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM85.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.98%
Return on Capital
10 Years-42.34%
5 Years-67.7%
3 Years-67.98%
Last Year-23.44%
LXRX Recent Earnings
Lexicon Pharmaceuticals, Inc. (LXRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.00+93.5%
$0.04
Rev
$21M+115.6%
$10M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
$5M+74.8%
$3M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
$14M+351.4%
$3M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.01+112.5%
$0.08
Rev
$29M+396.7%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.00vs $0.04+93.5% | $21Mvs $10M+115.6% |
| Q2 2026 | Mar 5, 2026 | $0.04vs $0.07+42.9% | $5Mvs $3M+74.8% |
| Q4 2025 | Nov 6, 2025 | $0.04vs $0.07+42.9% | $14Mvs $3M+351.4% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.08+112.5% | $29Mvs $6M+396.7% |
Based on last 12 quarters of dataView full earnings history →
LXRX Peer Comparison
Lexicon Pharmaceuticals, Inc. (LXRX) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CORT | 8.58B | 79.91 | 97.45 | 12.79% | 6.23% | 7.5% | 0.01 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% |
Compare LXRX vs Peers
Lexicon Pharmaceuticals, Inc. (LXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LXRX Income Statement
Lexicon Pharmaceuticals, Inc. (LXRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 90.33M | 63.21M | 322.07M | 24M | 298K | 139K | 1.2M | 31.08M | 49.8M | 69.64M |
Revenue Growth % | 8.4% | -30.03% | 409.54% | -92.55% | -98.76% | -53.36% | 766.19% | 2481.48% | 60.24% | 123.12% |
Cost of Goods Sold | 1.9M | 2.49M | 3.23M | 1.93M | 55.05M | 52.52M | 58.97M | 616K | 274K | 646K |
COGS % of Revenue | 2.1% | 3.94% | 1% | 8.04% | 18471.81% | 37781.29% | 4898.01% | 1.98% | 0.55% | - |
Gross Profit | 88.44M▲ 0% | 60.72M▼ 31.3% | 318.84M▲ 425.1% | 22.07M▼ 93.1% | -54.75M▼ 348.1% | -52.38M▲ 4.3% | -57.77M▼ 10.3% | 30.46M▲ 152.7% | 49.53M▲ 62.6% | 69M▲ 0% |
Gross Margin % | 97.9% | 96.06% | 99% | 91.96% | -18371.81% | -37681.29% | -4798.01% | 98.02% | 99.45% | 99.07% |
Gross Profit Growth % | 209.67% | -31.34% | 425.12% | -93.08% | -348.11% | 4.33% | -10.29% | 152.74% | 62.58% | - |
Operating Expenses | 223.02M | 164M | 177.4M | 69.87M | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M | 93.22M |
OpEx % of Revenue | 246.88% | 259.45% | 55.08% | 291.17% | 10853.02% | 34807.91% | 9466.94% | 732.22% | 197.66% | - |
Selling, General & Admin | 66.2M | 63.75M | 56.84M | 47.23M | 0 | 0 | 0 | 131.9M | 37.32M | 34.94M |
SG&A % of Revenue | 73.29% | 100.86% | 17.65% | 196.83% | - | - | - | 424.38% | 74.93% | - |
Research & Development | 156.81M | 100.24M | 91.92M | 153.62M | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M | 58.28M |
R&D % of Revenue | 173.59% | 158.59% | 28.54% | 640.22% | 18471.81% | 37997.12% | 4890.95% | 271.81% | 122.73% | - |
Other Operating Expenses | 1.95M | 0 | 28.64M | -130.99M | -22.7M | -4.43M | 55.09M | 11.2M | 0 | 0 |
Operating Income | -136.68M▲ 0% | -103.28M▲ 24.4% | 141.44M▲ 237.0% | -47.8M▼ 133.8% | -87.09M▼ 82.2% | -100.76M▼ 15.7% | -171.75M▼ 70.5% | -197.12M▼ 14.8% | -48.91M▲ 75.2% | -24.23M▲ 0% |
Operating Margin % | -151.3% | -163.39% | 43.92% | -199.21% | -29224.83% | -72489.21% | -14264.95% | -634.2% | -98.21% | -34.79% |
Operating Income Growth % | 0.35% | 24.44% | 236.95% | -133.79% | -82.2% | -15.7% | -70.45% | -14.77% | 75.19% | - |
EBITDA | -133.28M | -99.6M | 145.1M | -44.87M | -86.8M | -100.33M | -171.2M | -196.58M | -48.29M | -23.78M |
EBITDA Margin % | -147.54% | -157.57% | 45.05% | -186.98% | -29126.85% | -72182.01% | -14218.94% | -632.49% | -96.96% | -34.15% |
EBITDA Growth % | 1.34% | 25.27% | 245.69% | -130.92% | -93.46% | -15.59% | -70.63% | -14.83% | 75.44% | 86.56% |
D&A (Non-Cash Add-back) | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K | 621K | 445K |
EBIT | -128.67M | -99.77M | 144.79M | -44.03M | -87.09M | -100.46M | -170.31M | -184.82M | -48.91M | -20.82M |
Net Interest Income | -5.03M | -17.27M | -17.33M | -11.78M | -668K | -1.18M | -5.37M | -3.29M | -1.43M | -226K |
Interest Income | 1.95M | 3.51M | 3.35M | 2.77M | 134K | 1.6M | 7.73M | 12.29M | 6.91M | 4.69M |
Interest Expense | 6.98M | 20.78M | 20.68M | 14.54M | 802K | 2.78M | 13.1M | 15.58M | 8.34M | 4.91M |
Other Income/Expense | -5.03M | -17.27M | -17.33M | -10.77M | -668K | -1.18M | -5.37M | -3.29M | -1.43M | -1.86M |
Pretax Income | -141.71M▲ 0% | -120.55M▲ 14.9% | 124.12M▲ 203.0% | -58.57M▼ 147.2% | -87.76M▼ 49.8% | -101.94M▼ 16.2% | -177.12M▼ 73.7% | -200.4M▼ 13.1% | -50.34M▲ 74.9% | -26.09M▲ 0% |
Pretax Margin % | -156.87% | -190.71% | 38.54% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% | -37.46% |
Income Tax | -12.66M | 0 | -6.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 8.93% | 0% | -4.85% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -129.05M▲ 0% | -120.55M▲ 6.6% | 130.13M▲ 208.0% | -58.57M▼ 145.0% | -87.76M▼ 49.8% | -101.94M▼ 16.2% | -177.12M▼ 73.7% | -200.4M▼ 13.1% | -50.34M▲ 74.9% | -26.09M▲ 0% |
Net Margin % | -142.86% | -190.71% | 40.4% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% | -37.46% |
Net Income Growth % | 8.75% | 6.59% | 207.95% | -145.01% | -49.82% | -16.16% | -73.74% | -13.15% | 74.88% | 85.28% |
Net Income (Continuing) | -122.99M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M | -50.34M | -26.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.23▲ 0% | -1.14▲ 7.3% | 1.11▲ 197.4% | -0.63▼ 156.8% | -0.61▲ 3.2% | -0.62▼ 1.6% | -0.80▼ 29.0% | -0.63▲ 21.3% | -0.14▲ 77.8% | -0.07▲ 0% |
EPS Growth % | 9.56% | 7.32% | 197.37% | -156.76% | 3.17% | -1.64% | -29.03% | 21.25% | 77.78% | 85.98% |
EPS (Basic) | -1.23 | -1.14 | 1.23 | -0.63 | -0.61 | -0.62 | -0.80 | -0.63 | -0.14 | - |
Diluted Shares Outstanding | 105.24M | 105.83M | 116.75M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M | 400.24M |
Basic Shares Outstanding | 105.12M | 105.74M | 106.22M | 110.84M | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M | 400.24M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LXRX Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 322M | 173.32M | 337.75M | 157.72M | 88.92M | 140.87M | 176.55M | 246.19M | 101.89M | 186.03M |
Cash & Short-Term Investments | 310.79M | 160.05M | 271.66M | 152.28M | 86.74M | 138.36M | 170.03M | 237.96M | 96.23M | 170.66M |
Cash Only | 310.79M | 160.05M | 36.11M | 126.26M | 64.06M | 46.34M | 22.46M | 66.66M | 34.33M | 38.09M |
Short-Term Investments | 0 | 0 | 235.55M | 26.01M | 22.68M | 92.01M | 147.56M | 171.3M | 61.9M | 132.57M |
Accounts Receivable | 4.83M | 5.92M | 56.53M | 395K | 14K | 28K | 1.01M | 3.47M | 2.38M | 11.78M |
Days Sales Outstanding | 19.5 | 34.21 | 64.07 | 6.01 | 17.15 | 73.53 | 306.19 | 40.79 | 17.47 | 24.48 |
Inventory | 1.95M | 4.68M | 4.24M | 0 | 0 | 0 | 381K | 231K | 281K | 276K |
Days Inventory Outstanding | 374.42 | 685.75 | 479.32 | - | - | - | 2.36 | 136.88 | 374.32 | 124.73 |
Other Current Assets | 4.43M | 2.67M | 0 | 0 | 0 | 2.48M | 5.13M | 4.53M | 3M | 3.32M |
Total Non-Current Assets | 114.54M | 110.81M | 79.96M | 46.07M | 47.99M | 53.43M | 52.88M | 52.23M | 83.09M | 82.79M |
Property, Plant & Equipment | 17.69M | 15.87M | 14.05M | 295K | 3.44M | 8.48M | 7.51M | 7.32M | 9.18M | 8.88M |
Fixed Asset Turnover | 5.11x | 3.98x | 22.93x | 81.34x | 0.09x | 0.02x | 0.16x | 4.25x | 5.42x | 8.16x |
Goodwill | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M | 44.54M |
Intangible Assets | 51.88M | 50.12M | 19.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | -4.88M | -4.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 429K | 285K | 1.66M | 1.23M | 0 | 412K | 828K | 368K | 29.37M | 29.37M |
Total Assets | 436.54M▲ 0% | 284.14M▼ 34.9% | 417.71M▲ 47.0% | 203.79M▼ 51.2% | 136.91M▼ 32.8% | 194.3M▲ 41.9% | 229.43M▲ 18.1% | 298.42M▲ 30.1% | 184.99M▼ 38.0% | 268.82M▲ 0% |
Asset Turnover | 0.21x | 0.22x | 0.77x | 0.12x | 0.00x | 0.00x | 0.01x | 0.10x | 0.27x | 0.31x |
Asset Growth % | -8.22% | -34.91% | 47.01% | -51.21% | -32.82% | 41.92% | 18.08% | 30.07% | -38.01% | -123.16% |
Total Current Liabilities | 124.13M | 36.75M | 65.34M | 46.81M | 22.12M | 23.17M | 31.55M | 45.25M | 20.87M | 9.9M |
Accounts Payable | 38.76M | 12.05M | 12.18M | 5.47M | 9.15M | 10.39M | 14.39M | 14.8M | 3.08M | 3M |
Days Payables Outstanding | 7.45K | 1.77K | 1.38K | 1.03K | 60.69 | 72.25 | 89.06 | 8.77K | 4.11K | 2.23K |
Short-Term Debt | 14.09M | 1.11M | 11.01M | 11.65M | 0 | 0 | 0 | 0 | 6.24M | 1.64M |
Deferred Revenue (Current) | 40.1M | 3.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21.76M |
Other Current Liabilities | 252K | -1.06M | 9.64M | 6.2M | 5.71M | 3.66M | 9.59M | 14.71M | 11.55M | 5.26M |
Current Ratio | 2.59x | 4.72x | 5.17x | 3.37x | 4.02x | 6.08x | 5.60x | 5.44x | 4.88x | 18.79x |
Quick Ratio | 2.58x | 4.59x | 5.10x | 3.37x | 4.02x | 6.08x | 5.58x | 5.44x | 4.87x | 18.77x |
Cash Conversion Cycle | -7.06K | -1.05K | -832.34 | - | - | - | 219.49 | -8.59K | -3.72K | -2.08K |
Total Non-Current Liabilities | 260.31M | 273.79M | 235.27M | 611K | 1.19M | 54M | 104.77M | 107.22M | 56.58M | 56.06M |
Long-Term Debt | 231.58M | 243.89M | 234.17M | 0 | 0 | 48.58M | 99.51M | 100.3M | 49.41M | 49.68M |
Capital Lease Obligations | 0 | 0 | 1.1M | 611K | 1.19M | 5.42M | 5.26M | 6.92M | 6.59M | 12.97M |
Deferred Tax Liabilities | 6.01M | 6.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 292K | 238K | 0 | 0 | 0 | 0 | 0 | 0 | 582K | 0 |
Total Liabilities | 384.44M | 310.54M | 300.61M | 47.42M | 23.31M | 77.17M | 136.32M | 152.47M | 77.45M | 65.96M |
Total Debt | 245.67M | 245M | 246.84M | 12.81M | 2.28M | 55.29M | 106.06M | 108.4M | 62.24M | 57.71M |
Net Debt | -65.12M | 84.95M | 210.73M | -113.45M | -61.79M | 8.95M | 83.6M | 41.74M | 27.91M | 19.62M |
Debt / Equity | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x | 0.58x | 0.28x |
Debt / EBITDA | - | - | 1.70x | - | - | - | - | - | - | -2.43x |
Net Debt / EBITDA | - | - | 1.45x | - | - | - | - | - | - | -0.82x |
Interest Coverage | -18.42x | -4.80x | 7.00x | -3.03x | -108.59x | -36.14x | -13.00x | -11.86x | -5.87x | -4.24x |
Total Equity | 52.1M▲ 0% | -1.47B▼ 2924.4% | 117.1M▲ 108.0% | 156.37M▲ 33.5% | 113.59M▼ 27.4% | 117.12M▲ 3.1% | 93.11M▼ 20.5% | 145.95M▲ 56.8% | 107.54M▼ 26.3% | 202.86M▲ 0% |
Equity Growth % | -66.9% | -2924.42% | 107.96% | 33.54% | -27.36% | 3.11% | -20.5% | 56.75% | -26.32% | -40.19% |
Book Value per Share | 0.50 | -13.91 | 1.00 | 1.41 | 0.78 | 0.71 | 0.42 | 0.46 | 0.30 | 0.51 |
Total Shareholders' Equity | 52.1M | -1.47B | 117.1M | 156.37M | 113.59M | 117.12M | 93.11M | 145.95M | 107.54M | 202.86M |
Common Stock | 106K | 106K | 106K | 142K | 150K | 189K | 245K | 363K | 366K | 426K |
Retained Earnings | -1.38B | -1.47B | -1.34B | -1.4B | -1.49B | -1.59B | -1.77B | -1.97B | -2.02B | -2.02B |
Treasury Stock | -1.9M | -2.88M | -3.82M | -4.84M | -7.52M | -2.06M | -2.88M | -4.62M | -5.19M | -2.84M |
Accumulated OCI | -222K | -12K | 84K | -6K | -10K | -428K | 31K | 119K | 30K | -130K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXRX Cash Flow Statement
Lexicon Pharmaceuticals, Inc. (LXRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -185.39M | -148.61M | 113.81M | -142.97M | -87.02M | -88.85M | -161.9M | -178.78M | -67.85M | -38.8M |
Operating CF Margin % | -205.23% | -235.1% | 35.34% | -595.83% | -29200.34% | -63921.58% | -13446.59% | -575.21% | -136.24% | - |
Operating CF Growth % | -5.56% | 19.84% | 176.58% | -225.62% | 39.14% | -2.11% | -82.21% | -10.43% | 62.05% | 276.73% |
Net Income | -129.05M | -120.55M | 130.13M | -58.57M | -87.76M | -101.94M | -177.12M | -200.4M | -50.34M | -26.09M |
Depreciation & Amortization | 3.4M | 3.68M | 3.65M | 2.93M | 292K | 427K | 554K | 534K | 621K | 555K |
Stock-Based Compensation | 9.47M | 11.7M | 14.22M | 13.27M | 10.58M | 11.52M | 14.34M | 13.5M | 12.52M | 6.03M |
Deferred Taxes | -12.66M | 0 | -6.01M | -110K | 49K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.7M | 1.34M | 30.1M | -131.57M | 54K | 744K | -2.33M | -6.65M | -3.75M | 4.77M |
Working Capital Changes | -59.26M | -44.77M | -58.29M | 31.08M | -10.23M | 402K | 2.66M | 14.24M | -26.89M | -24.07M |
Change in Receivables | 166K | -1.1M | -50.61M | 53.23M | 381K | -14K | -982K | -2.46M | 1.09M | -9.33M |
Change in Inventory | -1.95M | -2.73M | 437K | 345K | 0 | 0 | -381K | 150K | -50K | -75K |
Change in Payables | -7.17M | -18.86M | 20.1M | -20.97M | -14.16M | 76K | 6.45M | 14.8M | -30.22M | -15.43M |
Cash from Investing | 50.52M | 169.58M | -155.85M | 380.76M | 2.11M | -71.08M | -49.94M | -15.38M | 113.02M | 2.17M |
Capital Expenditures | -228K | -95K | -70K | -87K | -1.22M | -1.33M | -470K | -1.03M | 0 | 0 |
CapEx % of Revenue | 0.25% | 0.15% | 0.02% | 0.36% | 409.73% | 953.96% | 39.04% | 3.32% | - | 0% |
Acquisitions | 0 | 0 | 155.78M | 11.01M | -3.33M | 69.75M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 50.75M | 169.67M | -155.78M | 160.38M | 3.33M | -69.75M | 0 | 9.3M | 3.71M | 1.65M |
Cash from Financing | 149.93M | -2.24M | -2.23M | -147.64M | 22.71M | 142.21M | 187.96M | 238.35M | -48.5M | 40.83M |
Debt Issued (Net) | 143.63M | -2M | -1.28M | -216.58M | -11.7M | 48.87M | 49.96M | 0 | -48M | -53M |
Equity Issued (Net) | 6.31M | -240K | -941K | -1.03M | 34.41M | -864K | 138M | 239.59M | 73K | 96.67M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.68M | -972K | -941K | -1.03M | -2.67M | -864K | -824K | -1.73M | 0 | 0 |
Other Financing | 0 | 0 | 0 | 69.97M | 0 | 94.2M | 0 | -1.24M | -572K | -2.84M |
Net Change in Cash | 15.06M▲ 0% | 18.73M▲ 24.3% | -44.27M▼ 336.4% | 90.15M▲ 303.6% | -62.2M▼ 169.0% | -17.72M▲ 71.5% | -23.88M▼ 34.8% | 44.19M▲ 285.1% | -3.33M▼ 107.5% | 4.2M▲ 0% |
Free Cash Flow | -185.62M▲ 0% | -148.7M▲ 19.9% | 113.74M▲ 176.5% | -143.06M▼ 225.8% | -88.24M▲ 38.3% | -90.18M▼ 2.2% | -162.37M▼ 80.1% | -179.81M▼ 10.7% | -67.85M▲ 62.3% | -38.8M▲ 0% |
FCF Margin % | -205.48% | -235.25% | 35.31% | -596.19% | -29610.07% | -64875.54% | -13485.63% | -578.52% | -136.24% | -55.72% |
FCF Growth % | -5.55% | 19.89% | 176.49% | -225.78% | 38.32% | -2.2% | -80.05% | -10.74% | 62.27% | 76.97% |
FCF per Share | -1.76 | -1.41 | 0.97 | -1.29 | -0.61 | -0.54 | -0.73 | -0.56 | -0.19 | -0.10 |
FCF Conversion (FCF/Net Income) | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x | 1.35x | 1.49x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LXRX Key Ratios
Lexicon Pharmaceuticals, Inc. (LXRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -123.2% | - | 111.13% | -42.84% | -65.01% | -88.37% | -168.5% | -167.66% | -39.72% | -18.64% |
Return on Invested Capital (ROIC) | - | - | 32.36% | -19.34% | -137.91% | -84.97% | -85.09% | -81.14% | -22.7% | -11.15% |
Gross Margin | 97.9% | 96.06% | 99% | 91.96% | -18371.81% | -37681.29% | -4798.01% | 98.02% | 99.45% | 99.07% |
Net Margin | -142.86% | -190.71% | 40.4% | -244.11% | -29448.99% | -73341.01% | -14710.88% | -644.78% | -101.08% | -37.46% |
Debt / Equity | 4.72x | - | 2.11x | 0.08x | 0.02x | 0.47x | 1.14x | 0.74x | 0.58x | 0.28x |
Interest Coverage | -18.42x | -4.80x | 7.00x | -3.03x | -108.59x | -36.14x | -13.00x | -11.86x | -5.87x | -4.24x |
FCF Conversion | 1.44x | 1.23x | 0.87x | 2.44x | 0.99x | 0.87x | 0.91x | 0.89x | 1.35x | 1.49x |
Revenue Growth | 8.4% | -30.03% | 409.54% | -92.55% | -98.76% | -53.36% | 766.19% | 2481.48% | 60.24% | 123.12% |
Related:LXRX Dividend History·LXRX Revenue History·LXRX Price History·LXRX P/E History·LXRX Financial Ratios·LXRX Institutional Holders
LXRX SEC Filings & Documents
Lexicon Pharmaceuticals, Inc. (LXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
LXRX Frequently Asked Questions
Lexicon Pharmaceuticals, Inc. (LXRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lexicon Pharmaceuticals, Inc. (LXRX) reported $69.6M in revenue for fiscal year 2025. This represents a 1382% increase from $4.7M in 1999.
Lexicon Pharmaceuticals, Inc. (LXRX) grew revenue by 60.2% over the past year. This is strong growth.
Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $26.1M for fiscal year 2025.
Dividend & Returns
Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity (ROE) of -39.7%. Negative ROE indicates the company is unprofitable.
Lexicon Pharmaceuticals, Inc. (LXRX) had negative free cash flow of $38.8M in fiscal year 2025, likely due to heavy capital investments.